What You Ought to Know:
– Carta Healthcare®, which ignites healthcare enchancment by unlocking the facility of medical knowledge, expanded the energy and capabilities of its AI-powered platform with the acquisition of Realyze Intelligence.
– The Realyze Intelligence answer leverages AI to match sufferers to medical trials to speed up analysis and cut back prices whereas offering sufferers with the newest advances in care.
Carta Healthcare and Realyze Intelligence: Reworking Medical Knowledge Administration with AI-Powered Options
Carta Healthcare and Realyze Intelligence are revolutionizing healthcare knowledge abstraction and evaluation by leveraging synthetic intelligence (AI) to handle inefficiencies and enhance affected person outcomes. Their superior platforms mix clinician experience with AI-driven automation to offer quicker, cost-effective, and high-quality insights into medical knowledge for oncology and past.
Carta Healthcare’s AI-Pushed Knowledge Abstraction
Carta Healthcare addresses the challenges of medical registry knowledge abstraction—historically labor-intensive, time-consuming, and expensive—via a mix of AI expertise and expert knowledgeable abstractors. This method delivers:
- Quicker and extra environment friendly knowledge abstraction.
- Price-effective options with out compromising knowledge high quality.
- Enhanced insights for medical registries and high quality efficiency applications throughout specialties like oncology and cardiovascular well being.
Realyze Intelligence: Accelerating Oncology Analysis
Realyze Intelligence focuses on quickly analyzing structured and unstructured digital well being report (EHR) knowledge to streamline affected person identification for medical trials and analysis. Key options embrace:
- Clinician-trained AI able to assembling affected person cohorts in seconds.
- Confirmed outcomes, resembling UPMC Hillman Most cancers Heart matching seven occasions extra sufferers to trials and doubling enrollment charges with Realyze’s software program.
- Adoption by main most cancers facilities, together with Memorial Sloan Kettering Most cancers Heart, and recognition by the CancerX Accelerator Program.
Synergistic Options for Pressing Challenges
With most cancers on monitor to surpass heart problems because the main international reason for dying, the necessity for strong, AI-enhanced options has by no means been larger. Challenges resembling unstructured affected person notes—the place over 80% of trial standards reside—are addressed by these platforms, considerably lowering handbook efforts. Moreover:
- Solely 7% of sufferers with most cancers at the moment take part in medical trials, although 50% would enroll if successfully recruited.
- Carta Healthcare and Realyze Intelligence increase trial feasibility, enhance recruitment, and speed up knowledge abstraction for most cancers and different registries.
Impression and Imaginative and prescient
By integrating clinician-trained AI with human oversight, Carta Healthcare and Realyze Intelligence ship actionable insights, dramatically cut back labor calls for, and improve analysis capabilities. Brent Dover, CEO of Carta Healthcare, emphasised their shared mission: “We consider knowledge is the only most necessary ingredient to enhance healthcare. By maximizing insights from medical knowledge, we intention to remodel care practices and affected person outcomes.”
Via their mixed improvements, Carta Healthcare and Realyze Intelligence are on the forefront of advancing medical analysis, addressing international well being challenges, and enabling precision medication.
